Day: April 9, 2020

Correction made in the announcement in the Latvian language only – corrected the date by which the completed powers of attorney and voting orders will be taken into account in the voting.   Joint stock company ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ announces that the Regular Shareholders’ Meeting of shareholders on 24 April, 2020 will be held on the basis of the previously announced agenda. However, considering the emergency situation in the Republic of Latvia due to the Covid-19 pandemic as announced by the order No.103 ‘On declaration of the emergency situation’ of 12 March, 2020 of the Cabinet of Ministers of the Republic of Latvia and to safeguard the shareholders and employees health condition as well as the public health in general, we kindly inform you that it is possible to participate at this meeting in a remote...

Labots datums, līdz kuram saņemtās aizpildītās pilnvaras un balsošanas uzdevumi tiks ņemti vērā balsojumā.Akciju sabiedrība “Siguldas ciltslietu un mākslīgās apsēklošanas stacija” paziņo, ka sabiedrības 2020. gada 24. aprīļa kārtējā akcionāru sapulce norisināsies, ievērojot iepriekš paziņoto dienaskārtību. Taču, ņemot vērā Covid-19 pandēmiju un ārkārtējo situāciju Latvijas Republikā, kas izsludināta ar Ministru kabineta 2020. gada 12. marta rīkojumu Nr. 103 “Par ārkārtējās situācijas izsludināšanu”, lai aizsargātu akcionāru, akciju sabiedrības darbinieku un sabiedrības veselību kopumā, informējam, ka šajā sapulcē ir iespējams piedalīties arī neklātienē – balsojot rakstveidā pirms sapulces.Akcionārus, kas vēlas balsot neklātienē, izskatāmo jautājumu izlemšanai lūdzam pilnvarot akciju sabiedrības “Siguldas ciltslietu un mākslīgās apsēklošanas...

ProVen VCT plc (the “Company”)Correction Re Issue of Equity Announcement8 April 2020Please note that the announcement below replaces the issue of equity announcement released on 5 March 2020. The Company issued 5,305,006 Ordinary Shares (and not 5,308,351 Ordinary Shares as originally announced). As stated, the correct figure (for the issued share capital and the denominator for the purposes of the total voting rights of the Company) on publication of the announcement should have been 155,583,344 (and not 155,586,689 as originally announced).  The stated average price for the shares allotted on 5 March 2020 is unaffected. The Company confirms that no changes are needed to its “Issue of equity” announcement dated 3 April 2020.ProVen VCT plc The Directors of ProVen VCT plc announce an allotment on 5 March 2020 of ordinary...

ProVen VCT plc (the “Company”)Correction Re Total Voting Rights Announcement8 April 2020Please note that the announcement below replaces the Total Voting Rights announcement released on 1 April 2020. On publication of the announcement, the issued share capital of the Company was 155,534,772 Ordinary Shares (and not 155,538,117) and likewise the denominator for the purposes of the total voting rights of the Company was 155,534,772 (and not 155,538,117 as originally announced).   ProVen VCT plcTotal Voting Rights1 April 2020In conformity with the Disclosure and Transparency Rule 5.6.1, ProVen VCT plc announces that the Company’s capital and voting rights, as at 31 March 2020, are summarised as follows:The Company does not hold any shares in treasury.            The above figure may be used by shareholders as the denominator...

Stockholm den 9 april 2020PRESSMEDDELANDEKALLELSE TILL ÅRSSTÄMMAi Hedera Group AB (publ)Aktieägarna i Hedera Group AB (publ), org. nr 556802-2155 (“Bolaget”), kallas härmed till årsstämma fredagen den 8 maj 2020 kl. 10:00. Bolagsstämman kommer att hållas på Advokatfirma DLA Piper Swedens kontor på Kungsgatan 9 i Stockholm.Rätt att delta vid bolagsstämman m.m.Aktieägare som vill delta på bolagsstämman ska dels i) vara införd i den av Euroclear Sweden AB förda aktieboken senast den 30 april 2020, dels ii) senast kl. 12:00 den 30 april 2020 anmäla sig för deltagande på bolagsstämman hos Bolaget via e-post till bertil.haglund@hederagroup.se eller per brev till Hedera Group AB (publ), Lästmakargatan 10, 111 44 Stockholm. Vid anmälan ska uppges namn, person- eller organisationsnummer och antal aktier som företräds samt ska eventuella...

VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq: CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX). Recently, researchers at the University of Frankfurt...

Bonum Pankki OyjSisäpiiritietoPörssitiedote 9.4.2020 klo 10.15Koronaepidemia lisää Bonum Pankki Oyj:n ja POP Pankki -ryhmän tulokseen liittyvää epävarmuuttaKoronaepidemian aiheuttama globaali kriisi on heikentänyt talouden näkymiä. Epävarmuus Bonum Pankki Oyj:n toimintaympäristössä on kasvanut, erityisesti pääomamarkkinoiden rahoituslähteiden ennakoitavuuden sekä vakuudettomien kulutusluottojen arvonalentumisten tulevan kehityksen osalta. Kokonaisvaikutuksia ei ole mahdollista vielä täysin arvioida. Bonum Pankki Oyj on aiemmin arvioinut kuluvan tilikauden tuloksen muodostuvan positiiviseksi. Bonum Pankki Oyj tulee tarkentamaan loppuvuoden näkymiä puolivuosikatsauksen yhteydessä 18.8.2020.Myös POP Pankki -ryhmän vuoden 2020 tulokseen liittyvä epävarmuus on kasvanut. Voimakkaan markkinavolatiliteetin arvioidaan heikentävän sijoitustoiminnan...

Bonum Bank PlcInside InformationStock Exchange Release 9 April 2020 at 10.15 The Coronavirus Pandemic adds uncertainty to the financial results of Bonum Bank Plc and POP Bank Group The worldwide crisis caused by the coronavirus pandemic has weakened the global economic outlooks. Uncertainty in the operational environment of Bonum Bank Plc has increased, especially with regards to the predictability of funding available in the capital markets and the future development of impairment of unsecured consumer loans. It is still too early to reliably estimate the overall effects. Previously Bonum Bank Plc has estimated a positive result for the entire financial year. Bonum Bank Plc will clarify the outlook for the second half of the financial year upon the release of the half-year financial report on 18 August 2020.Uncertainty has also increased...

Bonum Pankki OyjTulosjulkistamisajankohdatPörssitiedote 9.4.2020 klo 10.15Bonum Pankki Oyj:n ja POP Pankki -ryhmän puolivuosikatsaukset julkistetaan 18.8.2020Bonum Pankki Oyj ja POP Pankki -ryhmä julkaisevat 18.8.2020 puolivuosikatsaukset kaudelta 1.1.-30.6.2020.Bonum Pankki Oyj ja POP Pankki -ryhmäLisätietoja:Toimitusjohtaja Pekka Lemettinen, POP Pankkiliitto oskPuhelin: 040 5035 411, sähköposti: pekka.lemettinen@poppankki.fiToimitusjohtaja Pia Ali-Tolppa, Bonum Pankki OyjPuhelin: 050 303 1476, sähköposti: pia.ali-tolppa@poppankki.fiJakelu:Nasdaq Helsinki Oywww.poppankki.fi

Bonum Bank PlcFinancial CalendarStock Exchange Release 9 April 2020 at 10.15Bonum Bank Plc and POP Bank Group: Half-Year Financial Reports will be published on 18 August 2020Bonum Bank Plc and POP Bank Group will publish half-year financial reports for 1 January – 30 June 2020 on the 18th of August 2020.Bonum Bank Plc and POP Bank GroupFurther information:CEO Pekka Lemettinen, POP Bank Alliance CoopTel: +358 40 5035 411, email: pekka.lemettinen@poppankki.fiCEO Pia Ali-Tolppa, Bonum Bank PlcTel: +358 50 303 1476, email: pia.ali-tolppa@poppankki.fiDistribution:Nasdaq Helsinki www.bonumpankki.fiwww.poppankki.fi